Help me find a form for health professionals

We can help you find a form based on your role and tasks.

Select one or more of the options that apply to you.

When you post or fax a form to us you need to sign the manual form. We can't accept digital signatures with paper forms.

When you send a form to us through HPOS, we can accept digital signatures attached to electronic forms.

My role is
I want to
The form is for
Code Title
AC010 Consent to release an electronic Aged Care Client Record
AC011 Application for the Oxygen or Enteral Feeding Supplement
AC014 Aged care application for the dementia and cognition supplement in home care
AC021 Aged care entry record
AC024 Viability expansion component and homeless supplement assessment
AC027 Register or update for Aged Care web services
DB018 Application for bulk bill claim adjustment
DB020 Assignment of benefit Medicare bulk bill Webclaim
DB4E Bulk bill voucher - electronically transmitted claims
HW010 Application for approval, renewal or amendment of premises as an Accredited Pathology Laboratory
HW011 Approved Pathology Authority Application/Renewal
HW034 HI Service - application to amend a healthcare provider record
HW037 HI Service - Application to amend a healthcare organisation record
HW042 HI Service - application to amend an organisation officer's personal details
HW043 HI Service - application to amend details of a contracted service provider organisation record
HW044 HI Service - application to deactivate, reactivate or retire a healthcare organisation
HW059 Medicare Easyclaim enquiry
HW064 Positron emission tomography - statutory declaration
HW078 Request for pay group link
HW081 Private health insurer registrations and updates for ECLIPSE
HW083 Request to revoke or reissue a NASH PKI certificate
HW091 Simplified Billing manual claims batch header
IM011 Australian Immunisation Register (AIR) - immunisation medical exemption
IM013 Australian Immunisation Register (AIR) - immunisation history
IM017 Australian Immunisation Register (AIR) - ceasing correspondence and release of information
IM018 Australian Immunisation Register (AIR) - immunisation encounter
IP005 Practice Incentives change of practice details
IP006 Practice Incentives Program Teaching Payment claim
IP007 Practice Incentives Practice closure or withdrawal
IP011 General Practitioner Aged Care Access Incentive Payment banking details
IP017 Practice Incentives Program Indigenous Health Incentive patient registration and consent
IP027 Practice Incentives review of decision
MO003 Provider Directory Data authorised recipient data release application or renewal
MO008 Medical indemnity request to aggregate payments for the same claim
MO031 Statutory declaration ROCS - Medical practitioner who has ceased private or all remunerated medical practice due to retirement
MO032 Run off Cover Indemnity Scheme - medical certificate maternity
MO033 Statutory declaration ROCS - Deceased medical practitioner
MO034 Statutory declaration ROCS - Medical practitioner who has not engaged in either private or remunerated medical practice during the preceding 3 years
MO035 Statutory declaration ROCS - Overseas medical practitioner
MO036 Statutory declaration ROCS - Medical practitioner who has ceased medical practice because of permanent disability
MO037 Statutory declaration ROCS - Medical practitioner who has ceased medical practice because of maternity
MO038 Statutory declaration ROCS - Midwife ceased practice because of permanent disability
MO039 Statutory declaration ROCS - Midwife aged 65 years or older who has ceased practice
MO040 Statutory declaration ROCS - Deceased midwife
MO041 Statutory declaration ROCS - Midwife who has ceased practice
MO042 Statutory declaration - Midwife Professional Indemnity Scheme – Online claim
MO043 ROCS - midwife medical certificate for maternity form
MO044 Statutory declaration ROCS - Midwife engaged in a private practice
MO056 Run off Cover Indemnity Scheme - medical certificate permanent disability
MO057 Voluntary acknowledgement of incorrect payments
MO060 ROCS – midwife medical certificate for permanent disability
MO065 COVID-19 Vaccine Claims Scheme cost calculation
PB012 Myelodysplastic syndrome - lenalidomide - initial or first continuing authority application
PB042 Aboriginal Health Services (AHS) pharmaceutical supplies request
PB049 Stoma Appliance Scheme application
PB050 Stoma Appliance Scheme application for additional supplies for clinical and other reasons
PB060 Juvenile idiopathic arthritis initial authority application
PB061 Juvenile idiopathic arthritis continuing authority application
PB062 Juvenile idiopathic arthritis for adult patients with onset prior to age 18 initial authority application
PB063 Juvenile idiopathic arthritis for adult patients with onset prior to age 18 continuing authority application
PB070 Pulmonary arterial hypertension - initial monotherapy authority application
PB072 Subfoveal choroidal neovascularisation - initial authority application
PB073 Ankylosing spondylitis - initial authority application
PB074 Ankylosing spondylitis - continuing authority application
PB077 Acute lymphoblastic leukaemia – second line - dasatinib initial PBS authority application
PB079 Chronic myelomonocytic leukaemia - azacitidine - initial authority application
PB085 Crohn's disease paediatric initial authority application
PB087 Crohn's disease adult - initial authority application
PB088 Crohn’s disease adult - continuing authority application
PB092 Fistulising Crohn's disease - initial or recommencement (treatment break greater than 5 years) authority application
PB093 Fistulising Crohn's disease - continuing authority application
PB096 Gastrointestinal stromal tumour – sunitinib – initial authority application
PB097 Idiopathic thrombocytopenic purpura - eltrombopag or romiplostim - initial authority application
PB098 Idiopathic thrombocytopenic purpura – eltrombopag or romiplostim – first continuing or re-initiation of interrupted continuing authority application
PB099 Metastatic HER2 positive breast cancer - lapatinib - initial authority application
PB104 Narcolepsy without cataplexy - armodafinil or modafinil initial authority application
PB105 Psoriatic arthritis - initial authority application
PB106 Psoriatic arthritis - continuing authority application
PB109 Rheumatoid arthritis - initial authority application
PB111 Rheumatoid arthritis - continuing authority application
PB112 Severe chronic plaque psoriasis - initial authority application
PB113 Severe chronic plaque psoriasis - continuing authority application
PB114 PASI calculation and body diagram - face, hand and foot
PB115 PASI calculation and body diagram - whole body
PB116 Severe chronic plaque psoriasis - etanercept - for patients under 18 years initial, re-treatment, course completion, change or recommencing authority application
PB117 Systemic juvenile idiopathic arthritis initial PBS authority application
PB118 Systemic juvenile idiopathic arthritis continuing, retrial or recommencement or demonstration of response PBS authority application
PB120 Cystic fibrosis - ivacaftor - initial authority application
PB121 Alzheimer disease - initial PBS authority application
PB123 CD30 positive systemic anaplastic large cell lymphoma - brentuximab vedotin - initial authority application
PB126 Cystic fibrosis - ivacaftor - continuing authority application
PB127 Ulcerative colitis adult - initial authority application
PB136 Seemingly valid Medicare card
PB154 Retinal vein occlusion - initial PBS authority application
PB155 Diabetic macular oedema - initial PBS authority application
PB156 Non-small cell lung cancer - crizotinib or entrectinib - initial authority application
PB158 Multiple myeloma - progressive disease - lenalidomide initial authority application
PB161 Crohn's disease paediatric continuing authority application
PB162 Growth hormone - paediatric initial authority application
PB163 Growth hormone - continuing authority application
PB164 Growth hormone - paediatric continuing as a reclassified patient authority application
PB165 Growth hormone - recommencement authority application
PB166 Growth hormone - paediatric recommencement as a reclassified patient authority application
PB169 Acute lymphoblastic leukaemia - ponatinib initial authority application
PB171 Chronic myeloid leukaemia - ponatinib - initial authority application
PB172 Myelofibrosis - initial PBS authority application
PB174 Polyangiitis – induction or re-induction of remission PBS authority application
PB175 Atypical haemolytic uraemic syndrome (aHUS) - eculizumab extended initial PBS authority application Supporting information
PB181 Acromegaly - pasireotide initial PBS authority application
PB185 PBS Safety Net stationery order for pharmacies
PB189 Severe allergic asthma patients initiated under paediatric severe allergic asthma continuing authority application
PB192 Chronic thromboembolic pulmonary hypertension - initial PBS authority application
PB200 Multiple myeloma - newly diagnosed - lenalidomide dual therapy initial PBS authority application
PB205 Relapsed or refractory Hodgkin lymphoma - brentuximab (failed autologous stem cell transplant (ASCT) or is ASCT naïve) initial PBS authority
PB206 Metastatic or locally advanced basal cell carcinoma - sonidegib or vismodegib Initial authority application Supporting information
PB207 Metastatic or locally advanced basal cell carcinoma - sonidegib or vismodegib Continuing authority application Supporting information
PB208 Idiopathic pulmonary fibrosis initial authority application
PB210 Acute lymphoblastic leukaemia – blinatumomab Initial (Induction) authority application
PB214 Multiple myeloma - pomalidomide initial authority application
PB215 Ulcerative colitis - paediatric - initial authority application
PB216 Cutaneous T- cell lymphoma (CTCL) - vorinostat Initial authority application
PB218 Moderate to severe hidradenitis suppurativa initial authority application
PB219 Moderate to severe hidradenitis suppurativa continuing authority application
PB223 Severe chronic spontaneous urticaria - omalizumab - initial authority application
PB225 Acromegaly - pegvisomant initial PBS authority application
PB229 Order for PBS or RPBS computer prescription forms for all eligible prescribers
PB232 Relapsed or refractory Hodgkin lymphoma - pembrolizumab initial PBS authority application
PB233 Spinal muscular atrophy - nusinersen or risdiplam - 18 years or younger - initial authority application
PB235 Crohn’s disease adult - change, recommencement or demonstration of response authority application
PB236 Fistulising Crohn’s disease - change, recommencement (treatment break less than 5 years) or demonstration of response authority application
PB239 Crohn's disease paediatric change or recommencement authority application
PB241 PBS Safety Net claim for payment
PB242 Approved supplier manual payment reconciliation
PB243 Cystic fibrosis - lumacaftor+ivacaftor or tezacaftor+ivacaftor - initial authority application
PB244 Cystic fibrosis - lumacaftor+ivacaftor or tezacaftor+ivacaftor - continuing authority application
PB245 Ulcerative colitis adult - change or recommencement authority application
PB246 Ulcerative colitis paediatric change or recommencement authority application
PB247 Rheumatoid arthritis - change, recommencement or demonstration of response authority application
PB248 Growth hormone deficiency - somatropin - late onset initial authority application
PB251 Ankylosing spondylitis - change, recommencement or demonstration of response authority application
PB253 Acute myeloid leukaemia - midostaurin - initial maintenance authority application
PB255 Non-radiographic axial spondyloarthritis initial authority application
PB259 Manual Prescription processing fee
PB260 Psoriatic arthritis - change, recommencement or demonstration of response authority application
PB263 Severe chronic plaque psoriasis - change, recommencement or demonstration of response authority application
PB266 Severe chronic plaque psoriasis - risankizumab - initial grandfather authority application
PB268 Cutaneous T-cell lymphoma (CTCL) - brentuximab vedotin - initial authority application
PB269 Acute lymphoblastic leukaemia - inotuzumab ozogamicin initial (induction) authority application
PB271 Acute lymphoblastic leukaemia – first line- dasatinib initial PBS authority application
PB272 Giant cell arteritis initial authority application
PB275 Short bowel syndrome with intestinal failure initial PBS authority application
PB276 Short bowel syndrome with intestinal failure first continuing PBS authority application
PB277 Short bowel syndrome with intestinal failure recommencement of treatment authority application
PB279 Short bowel syndrome with intestinal failure subsequent continuing authority application
PB281 Juvenile idiopathic arthritis change or recommencement or demonstration of response authority application
PB282 Juvenile idiopathic arthritis for adult patients with onset prior to age 18 change or recommencement or demonstration of response authority application
PB283 Order for PBS/RPBS prescription pads for all eligible prescribers
PB285 Severe asthma - adolescent and adult change authority application
PB286 Cystic fibrosis - elexacaftor+tezacaftor+ivacaftor - initial authority application
PB287 Cystic fibrosis - elexacaftor+tezacaftor+ivacaftor - continuing authority application
PB288 Growth hormone deficiency - somatropin - childhood onset initial authority application
PB289 Early HER2 positive breast cancer - trastuzumab emtansine - initial authority application
PB291 Multiple myeloma - newly diagnosed - monotherapy lenalidomide initial PBS authority application
PB293 Multiple myeloma - newly diagnosed - lenalidomide triple therapy initial PBS authority application
PB294 General (S85) Schedule - opioid treatment authority application
PB296 Relapsed or refractory primary mediastinal B-Cell lymphoma – pembrolizumab initial PBS authority application
PB301 Pulmonary arterial hypertension - initial grandfather dual therapy authority application
PB302 Medicine export declaration
PB303 Pulmonary arterial hypertension - initial dual therapy authority application
PB306 Palliative Care Schedule - opioid treatment authority application
PB309 Crohn’s disease adult - vedolizumab (subcutaneous form) - initial grandfather authority application
PB310 Ulcerative colitis adult - vedolizumab (subcutaneous form) - initial grandfather authority application
PB311 Spinal muscular atrophy - risdiplam initial grandfather authority application
PB312 Ankylosing spondylitis - upadacitinib - initial grandfather authority application
PB313 Psoriatic arthritis - upadacitinib - initial grandfather authority application
PB314 Peripheral T-cell lymphoma (PTCL) - brentuximab vedotin - initial authority application
PB317 Subfoveal choroidal neovascularisation - brolucizumab - initial grandfathered authority application
PB318 Severe chronic plaque psoriasis - ustekinumab - for patients under 18 years initial grandfather authority application
PB319 Severe chronic plaque psoriasis - ustekinumab - for patients under 18 years continuing authority application
PB320 Severe chronic plaque psoriasis ustekinumab - for patients under 18 years initial, change, recommencement or demonstration of response authority application
PB321 Rheumatoid arthritis - change or first continuing treatment due to critical shortage of tocilizumab authority application
PB322 Juvenile idiopathic arthritis – change or first continuing treatment due to critical shortage of tocilizumab authority application
PB323 Juvenile idiopathic arthritis - change of treatment after resolution of critical shortage of tocilizumab authority application
PB324 Rheumatoid arthritis - change of treatment after resolution of critical shortage of tocilizumab authority application
PB325 Hereditary angioedema type 1 or 2 - lanadelumab - initial authority application
PB326 Hereditary angioedema type 1 or 2 - lanadelumab - grandfather authority application
PB327 Paroxysmal nocturnal haemoglobinuria - eculizumab or ravulizumab - initial, switching due to pregnancy or balance of supply authority application
PB328 Paroxysmal nocturnal haemoglobinuria - eculizumab or ravulizumab - continuing authority application
PB329 Paroxysmal nocturnal haemoglobinuria - eculizumab or ravulizumab - initial grandfather authority application
PB330 Spinal muscular atrophy - onasemnogene abeparvovec authority application
PB331 Progressive fibrosing interstitial lung disease - nintedanib - initial grandfather authority application
PB332 Progressive fibrosing interstitial lung disease - nintedanib - initial authority application
PB333 Solid tumours - NTRK gene fusion positive - larotrectinib - initial authority application
PB334 Spinal muscular atrophy - nusinersen - 19 years or older - initial authority application
PB335 Spinal muscular atrophy - nusinersen - 19 years or older - initial grandfather authority application
SU415 Centrelink Medical Certificate

Page last updated: 10 December 2021